Checkpoint Inhibitor

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A. Madan, Christopher R. Heery, James L. Gulley, Jeffrey Schlom

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 20; DOI: 10.1186/s40425-017-0220-y
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Eileen Shiuan, Kathryn E. Beckermann, Alpaslan Ozgun, Ciara Kelly, Meredith McKean, Jennifer McQuade, Mary Ann Thompson, Igor Puzanov, John P. Greer, Suthee Rapisuwon, Michael Postow, Michael A. Davies, Zeynep Eroglu, Douglas Johnson

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 8; DOI: 10.1186/s40425-017-0210-0
A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
Jan Baughman, Deryk Loo, Francine Chen, Paul Moore, Ezio Bonvini, James Vasselli, Jon Wigginton, Roger Cohen

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P177; DOI: 10.1186/2051-1426-3-S2-P177
Targeting KIT on innate immune cells enhances the antitumor activity of checkpoint inhibitors in vivo
Richard Gedrich, Scott Seibel, Theresa LaVallee, Joseph Paul Eder

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) O12; DOI: 10.1186/2051-1426-3-S2-O12
Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
Heddy Bartell, Jedd Wolchok, F Stephen Hodi, Helen Liu, Cynthia Wojtaszek, Jeffrey Weber

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P384; DOI: 10.1186/2051-1426-3-S2-P384
INT230-6 shows strong synergy with anti-PD-1 and can induce high complete response rates with T cell memory response in a colon cancer mouse model
Anja C Bloom, Lewis H Bender, Masaki Terabe, Jay A Berzofsky, Ian B Walters

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P352; DOI: 10.1186/2051-1426-3-S2-P352
Checkpoint inhibitors synergize with therapeutic platforms, ZVex™ and GLAAS™ by enhancing lentiviral vector-induced tumor-specific immunity and adjuvant-mediated anti-tumor efficacy
Tina C Albershardt, Andrea J Parsons, Jan ter Meulen, Peter Berglund

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P346; DOI: 10.1186/2051-1426-3-S2-P346
Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models
Xingfeng Bao, Diana Albu, Kuan-Chun Huang, Jiayi Wu, Natalie Twine, Kenichi Nomoto, Mary Woodall-Jappe

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P350; DOI: 10.1186/2051-1426-3-S2-P350
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
John Powderly, Gregory Cote, Keith Flaherty, Russell Z Szmulewitz, Antoni Ribas, Jeffrey Weber, Deryk Loo, Jan Baughman, Francine Chen, Paul Moore, Ezio Bonvini, James Vasselli, Jon Wigginton, Roger Cohen, Howard Burris, Bartosz Chmielowski

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) O8; DOI: 10.1186/2051-1426-3-S2-O8
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
Matthew Taylor, Scott Antonia, Johanna Bendell, Emiliano Calvo, Dirk Jäger, Filippo de Braud, Patrick A Ott, M Catherine Pietanza, Leora Horn, Dung T Le, Michael A Morse, José A López-Martin, Paolo A Ascierto, Olaf Christensen, Jason S Simon, Chen-Sheng Lin, Joseph Paul Eder

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P376; DOI: 10.1186/2051-1426-3-S2-P376

Main menu

Checkpoint Inhibitor

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Checkpoint Inhibitor

Pages